1. Epithelial markers in pancreatic carcinoma: immunoperoxidase localisation of DD9, CEA, EMA and CAM 5.2;Heyderman, E.; Larkin, S.E.; O'Donnell, P.J.; Haines, A.M.; Warren, P.J.; Northeast, A.;J Clin Pathol,1990
2. Correlation of prostate-specific acid phosphatase and prostate-specific antigen immunocytochemistry with survival in prostate carcinoma;Hammond, M.E.; Sause, W.T.; Martz, K.L.; Pilepich, M.V.; Asbell, S.O.; Rubin, P.;Cancer,1989
3. Immunophenotypic analysis of colorectal carcinomas with monoclonal antibodies 47D10 and anti-carcinoembryonic antigen;Keep, J.C.; Benson, A.B.; Sullivan, M.D.; Camey, W.P.; Rosen, S.T.; Radosevich, J.A.;Tumour Biol,1989
4. Identification of primary tumour site by immunolocalization of progastricsin in metastatic adenocarcinoma;Reid, W.A.; Branch, T.; Gorman, C.;J Pathol,1990
5. A CAl 25 score as a prognostic index in patients with ovarian cancer;Rosen, A.; Sevelda, P.; Klein, M.; Spona, J.; Beck, A.;Arch Gynecol Obstet,1990